NYSE: RVTY
Revvity
Health Care · Laboratory Analytical Instruments
52-week range
$81.22$169.06
Stock price
Market cap
At each fiscal year end, then the latest quarter end: closing price × shares outstanding.Figures shown are for the trailing 12 months to Jul 5, 2026. Hover or tap a column for another year.$12.7B
Show tableHide table
| Period | Market cap |
|---|---|
| FY2016, ended Jan 1, 2017 | $5.73B |
| FY2017, ended Dec 31, 2017 | $8.08B |
| FY2018, ended Dec 30, 2018 | $8.56B |
| FY2019, ended Dec 29, 2019 | $10.8B |
| FY2020, ended Jan 3, 2021 | $16.1B |
| FY2021, ended Jan 2, 2022 | $25.4B |
| FY2022, ended Jan 1, 2023 | $17.7B |
| FY2023, ended Dec 31, 2023 | $13.5B |
| FY2024, ended Dec 29, 2024 | $13.5B |
| FY2025, ended Dec 28, 2025 | $10.8B |
| Trailing 12 months to Jul 5, 2026 (through Q2 FY2026) | $12.7B |
Revenue
By fiscal year, then the trailing 12 months.Figures shown are for the trailing 12 months to Jul 5, 2026. Hover or tap a column for another year.$2.91B
Show tableHide table
| Period | Revenue |
|---|---|
| FY2016, ended Jan 1, 2017 | $2.12B |
| FY2017, ended Dec 31, 2017 | $2.26B |
| FY2018, ended Dec 30, 2018 | $2.78B |
| FY2019, ended Dec 29, 2019 | $2.88B |
| FY2020, ended Jan 3, 2021 | $3.78B |
| FY2021, ended Jan 2, 2022 | $3.83B |
| FY2022, ended Jan 1, 2023 | $3.31B |
| FY2023, ended Dec 31, 2023 | $2.75B |
| FY2024, ended Dec 29, 2024 | $2.76B |
| FY2025, ended Dec 28, 2025 | $2.86B |
| Trailing 12 months to Jul 5, 2026 (through Q2 FY2026) | $2.91B |
Net income and free cash flow
By fiscal year, then the trailing 12 months. Free cash flow is operating cash flow minus capex.Figures shown are for the trailing 12 months to Jul 5, 2026. Hover or tap a column for another year.Show tableHide table
| Period | Net income | Free cash flow |
|---|---|---|
| FY2016, ended Jan 1, 2017 | $234M | $319M |
| FY2017, ended Dec 31, 2017 | $293M | $249M |
| FY2018, ended Dec 30, 2018 | $238M | $218M |
| FY2019, ended Dec 29, 2019 | $228M | $287M |
| FY2020, ended Jan 3, 2021 | $728M | $829M |
| FY2021, ended Jan 2, 2022 | $943M | $1.32B |
| FY2022, ended Jan 1, 2023 | $569M | $594M |
| FY2023, ended Dec 31, 2023 | $693M | $9.90M |
| FY2024, ended Dec 29, 2024 | $270M | $542M |
| FY2025, ended Dec 28, 2025 | $241M | $509M |
| Trailing 12 months to Jul 5, 2026 (through Q2 FY2026) | $238M | $558M |
Cash and cash equivalents
At each fiscal year end, then the latest quarter end.Figures shown are for the trailing 12 months to Jul 5, 2026. Hover or tap a column for another year.$1.02B
Show tableHide table
| Period | Cash and cash equivalents |
|---|---|
| FY2016, ended Jan 1, 2017 | $359M |
| FY2017, ended Dec 31, 2017 | $202M |
| FY2018, ended Dec 30, 2018 | $163M |
| FY2019, ended Dec 29, 2019 | $192M |
| FY2020, ended Jan 3, 2021 | $387M |
| FY2021, ended Jan 2, 2022 | $603M |
| FY2022, ended Jan 1, 2023 | $454M |
| FY2023, ended Dec 31, 2023 | $913M |
| FY2024, ended Dec 29, 2024 | $1.16B |
| FY2025, ended Dec 28, 2025 | $920M |
| Trailing 12 months to Jul 5, 2026 (through Q2 FY2026) | $1.02B |
Total debt
At each fiscal year end, then the latest quarter end. Short- and long-term borrowings, excluding leases.Figures shown are for the trailing 12 months to Jul 5, 2026. Hover or tap a column for another year.$3.21B
Show tableHide table
| Period | Total debt |
|---|---|
| FY2016, ended Jan 1, 2017 | $1.05B |
| FY2017, ended Dec 31, 2017 | $2.01B |
| FY2018, ended Dec 30, 2018 | $1.89B |
| FY2019, ended Dec 29, 2019 | $2.07B |
| FY2020, ended Jan 3, 2021 | $1.99B |
| FY2021, ended Jan 2, 2022 | $4.98B |
| FY2022, ended Jan 1, 2023 | $4.39B |
| FY2023, ended Dec 31, 2023 | $3.90B |
| FY2024, ended Dec 29, 2024 | $3.15B |
| FY2025, ended Dec 28, 2025 | $3.22B |
| Trailing 12 months to Jul 5, 2026 (through Q2 FY2026) | $3.21B |
Shares outstanding
At each fiscal year end, then the latest quarter end, adjusted for splits. Up 1.6% since 2016.Figures shown are for the trailing 12 months to Jul 5, 2026. Hover or tap a column for another year.112M
Show tableHide table
| Period | Shares outstanding |
|---|---|
| FY2016, ended Jan 1, 2017 | 110M |
| FY2017, ended Dec 31, 2017 | 111M |
| FY2018, ended Dec 30, 2018 | 111M |
| FY2019, ended Dec 29, 2019 | 111M |
| FY2020, ended Jan 3, 2021 | 112M |
| FY2021, ended Jan 2, 2022 | 126M |
| FY2022, ended Jan 1, 2023 | 126M |
| FY2023, ended Dec 31, 2023 | 124M |
| FY2024, ended Dec 29, 2024 | 120M |
| FY2025, ended Dec 28, 2025 | 112M |
| Trailing 12 months to Jul 5, 2026 (through Q2 FY2026) | 112M |
Buybacks and new shares
By fiscal year, then the trailing 12 months, in dollars. Below zero: bought back. Above zero: issued to employees, sold or used in acquisitions.Figures shown are for the trailing 12 months to Jul 5, 2026. Hover or tap a column for another year.Net: $451M more bought back than issued
Show tableHide table
| Period | Bought back | Paid to employees | Used in acquisitions |
|---|---|---|---|
| FY2016, ended Jan 1, 2017 | $152M | $17.2M | — |
| FY2017, ended Dec 31, 2017 | $3.83M | $25.4M | — |
| FY2018, ended Dec 30, 2018 | $57.4M | $28.8M | — |
| FY2019, ended Dec 29, 2019 | $6.31M | $31.5M | — |
| FY2020, ended Jan 3, 2021 | $6.94M | $26.9M | — |
| FY2021, ended Jan 2, 2022 | $73.1M | $29.7M | $2.64B |
| FY2022, ended Jan 1, 2023 | $80.6M | $51.5M | — |
| FY2023, ended Dec 31, 2023 | $389M | $41.4M | — |
| FY2024, ended Dec 29, 2024 | $370M | $37.8M | — |
| FY2025, ended Dec 28, 2025 | $821M | $22.8M | — |
| Trailing 12 months to Jul 5, 2026 (through Q2 FY2026) | $476M | $24.4M | — |
Revenue (TTM)
$2.91B
+4.1% YoY
Net income (TTM)
$238M
−16.7% YoY
Cash
$1.02B
+3.1% YoY
Total debt
$3.21B
−0.3% YoY
Valuation
At current price- Market Cap
- $17.5B
- P/E
- 73.7×
- Forward P/E
- —. Needs analyst estimates; not available from the current data provider
- Price / Sales
- 6.0×
- Price / Book
- 2.4×
- EV / EBITDA
- 25.6×
Growth
Trailing 12 months- Revenue (TTM)
- $2.91B
- Revenue Growth YoY
- 4.1%
- Revenue CAGR 3Y
- −4.8%
- Revenue CAGR 5Y
- −5.5%
- EPS Growth YoY
- −11.5%
- Net Income Growth YoY
- −16.7%
Profitability
Trailing 12 months- Gross Margin
- —
- Operating Margin
- 12.3%
- Net Margin
- 8.2%
- FCF Margin
- 19.2%
- Return on Equity
- 3.2%
Earnings
Trailing 12 months- Net Income
- $238M
- EPS (diluted)
- $2.08
- EBITDA
- $771M
- Operating Income
- $359M
Balance Sheet
As of Jul 5, 2026- Cash and cash equivalents
- $1.02B
- Total Debt
- $3.21B
- Net Debt
- $2.18B
- Total Assets
- $12.0B
- Total Liabilities
- $4.82B
- Shareholders' Equity
- $7.23B
Cash Flow
Trailing 12 months- Operating Cash Flow
- $628M
- Capital Expenditure
- $69.5M
- Free Cash Flow
- $558M
Dividends and risk
Last 12 months- Dividend Yield
- 0.2%
- Dividend / Share
- $0.28
- Beta (5Y)
- 1.07
Every ratio is calculated from the company’s reported figures.
Note
Revenue is roughly flat year over year at $2.91B.
Note
Net margin of 8.2% over the last 12 months.
Note
Net debt of $2.18B is 2.8× EBITDA.
Strength
Turns 19.2% of revenue into free cash flow.
Written by fixed rules from the reported figures, not by a person or an AI.
Latest report
Pro10-K for the fiscal year ended Dec 28, 2025 · filed Feb 24, 2026
The score and findings for the newest report are part of CoreStock Pro, coming soon. Every earlier report is free.
Score of each annual report
0 to 100 · 60 means nothing notable · tap a column for its details
2024 · 10-K69Mildly positive
69Mildly positive
10-K for the fiscal year ended Dec 29, 2024
Filed Feb 25, 2025 · Read the filing on EDGAR
- Revenue was flat at $2.755 billion, but income from continuing operations rose about 58% to $283.1 million on cost cuts and lower other expenses.
- Total net income fell sharply only because the prior year included the large gain on selling the Applied, Food and Enterprise Services businesses.
- Diagnostics revenue rose 3% and its profit rose 16%, while Life Sciences revenue fell 3% and its profit fell 8%.
- Operating cash flow more than doubled to $665.0 million; the company repaid its 2024 notes and authorized a new $1.0 billion buyback.
Business momentum
Improving
“Our consolidated operating margin increased 166 basis points in fiscal year 2024, as compared to fiscal year 2023, due to productivity initiatives and cost containment.”
Outlook
Positive
“provides us with a foundation for continued long-term growth, margin expansion and robust cash flow generation”
Financial stress
Low
“At December 29, 2024, we had cash and cash equivalents of $1,163.4 million, of which $562.6 million was held by our non-U.S. subsidiaries, and we had $1.5 billion of borrowing capacity available”
Tone against the previous report
More positive
Red flags
- Minor
Large write-down
“The above decreases were partially offset by an increase in asset impairments, which added an incremental expense of $22.8 million for fiscal year 2024.”
- Minor
Other
“During the fourth quarter of fiscal year 2024, we voluntarily changed our annual goodwill impairment testing date”
Positives
Operating cash flow more than doubled
“Net cash provided by continuing operations was $665.0 million for fiscal year 2024, as compared to $279.4 million for fiscal year 2023”
Diagnostics profit grew strongly
“Segment operating income for fiscal year 2024 was $372.4 million, as compared to $320.1 million for fiscal year 2023, an increase of $52.3 million, or 16%.”
Debt repaid and new buyback authorized
“During fiscal year 2024, we paid in full $711.5 million of outstanding 0.850% Senior Unsecured Notes that became due in September 2024”
Concerns
Life Sciences sales and profit fell on weak drug and biotech demand
“Segment operating income for fiscal year 2024 was $448.0 million, as compared to $489.3 million for fiscal year 2023, a decrease of $41.3 million, or 8%.”
Limited cushion on $4.3 billion of Life Sciences goodwill
“had a fair value that exceeded its carrying value by more than 10% but less than 20% as of the November 1, 2024 impairment testing date”
Gross margin slipped on product mix and costs
“due to an unfavorable shift in product mix and higher product costs, partially offset by pricing actions and productivity initiatives”
Biggest risks named
- Weak end markets, including drug and biotech spending and government funding
- Possible write-downs of $9.1 billion in intangible assets, especially Life Sciences
- Substantial debt with covenants and financial ratio requirements
- Currency, sanctions, war and other foreign risks, with about 60% of business outside the US
- Competition, new product execution and making acquisitions profitable
Artificial intelligence in this business: Not mentioned
How the score adds up
| Starting point | 60 | |
| Business momentum | +6 | |
| Outlook | +3 | |
| Tone against the previous report | +2 | |
| Financial stress | 0 | |
| Red flags | −2.4 | |
| New risks | 0 | |
| Score | 69 | |
Written by AI (Claude Opus 5.5) from the report’s text. 11 of 11 quotes were found word for word in the filing; the rest are left out. Not investment advice.
All scored reports
| Period | Report | Filed | Score | Momentum | Red flags |
|---|---|---|---|---|---|
| 10-K | Feb 24, 2026 | Pro | |||
| 10-K | Feb 25, 2025 | 69 | Improving | 2 minor | |
| 10-K | Feb 27, 2024 | 46 | Sharp deterioration | None | |
| 10-K | Mar 1, 2023 | 45 | Sharp deterioration | None | |
| 10-K | Mar 3, 2022 | 74 | Strong improvement | None | |
| 10-K | Mar 2, 2021 | 75 | Strong improvement | None | |
| 10-K | Feb 25, 2020 | 68 | Improving | None | |
| 10-K | Feb 26, 2019 | 74 | Strong improvement | None | |
| 10-K | Feb 27, 2018 | 65 | Improving | 1 medium | |
| 10-K | Feb 28, 2017 | 68 | Improving | None |
How these scores work
An AI model reads the management discussion, risk factors and legal sections of each report and records what they say, quoting the filing word for word. Fixed rules then turn those findings into a score from 0 to 100, where 60 means nothing notable either way. A score describes the report, not whether the stock is a good investment, and the AI may know how things turned out later, which can colour older scores. Read the methodology
From the 10-Q for Q2 FY2026 (period ended Jul 5, 2026), filed Aug 11, 2026. View filings on SEC EDGAR